

Milne P, Bigley V, Bacon CM, Néel A, McGovern N, Bomken S, Haniffa M,  
Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M,  
McClain KL, Allen C, Abdel-Wahab O, Collin M.

[Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester  
disease in adults.](#)

*Blood* (2017)

DOI: <https://doi.org/10.1182/blood-2016-12-757823>

**Copyright:**

Copyright © 2017 American Society of Hematology.

**DOI link to article:**

<https://doi.org/10.1182/blood-2016-12-757823>

**Date deposited:**

21/06/2017

**Embargo release date:**

16 May 2018

## **Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester disease in adults**

**Running Title: hematopoietic origin of adult histiocytosis**

Paul Milne<sup>1</sup>, Venetia Bigley<sup>1</sup>, Chris M. Bacon<sup>2,3</sup>, Antoine Néel<sup>4</sup>, Naomi McGovern<sup>1</sup>, Simon Bomken<sup>2</sup>, Muzlifah Haniffa<sup>1</sup>, Eli L. Diamond<sup>5</sup>, Benjamin H. Durham<sup>5</sup>, Johannes Visser<sup>6</sup>, David Hunt<sup>7</sup>, Harsha Gunawardena<sup>8</sup>, Mac Macheta<sup>9</sup>, Kenneth L. McClain<sup>10</sup>, Carl Allen<sup>10</sup>, Omar Abdel-Wahab<sup>5</sup> and Matthew Collin<sup>1</sup>

<sup>1</sup> Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK

<sup>2</sup> Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK

<sup>3</sup> Department of Cellular Pathology, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

<sup>4</sup> Internal Medicine Department, Hôtel-Dieu University Hospital, Nantes, France

<sup>5</sup> Memorial Sloan Kettering Cancer Center, New York, USA

<sup>6</sup> East Midlands Children's and Young Persons' Integrated Cancer Service, Leicester Children's Hospital, Leicester, UK

<sup>7</sup> MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

<sup>8</sup> Rheumatology Department, North Bristol NHS Trust, Bristol, UK

<sup>9</sup> Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK

<sup>10</sup> Texas Children's Cancer Center, Baylor College of Medicine, Houston, USA

Corresponding and communicating author:

Matthew Collin

Human Dendritic Cell Lab

Institute of Cellular Medicine

Newcastle University

Framlington Place

Newcastle upon Tyne NE2 4HH

UK

Tel: 44 191 213 9382

Email: [matthew.collin@ncl.ac.uk](mailto:matthew.collin@ncl.ac.uk)

### Key points

- 1) Bone marrow progenitors, monocytes and myeloid dendritic cells contain *BRAF*<sup>V600E</sup> alleles in adults with LCH and ECD
- 2) Mutant allele distribution is not disease-specific but precursors have distinct LCH-like and macrophage differentiation capacities

Abstract: 248; Words: 4224; Tables: 1; Figures: 6.

Keywords: *BRAF*<sup>V600E</sup>; Langerhans cell histiocytosis; Erdheim Chester Disease

**Word count 3355**

## Abstract

Langerhans cell histiocytosis (LCH) and Erdheim Chester Disease (ECD) are rare histiocytic disorders induced by somatic mutation of MAP kinase pathway genes. *BRAF*<sup>V600E</sup> mutation is the most common mutation in both conditions and also occurs in the hematopoietic neoplasm hairy cell leukemia (HCL). It is not known if adult LCH or ECD arise from hematopoietic stem cells (HSC) nor which potential blood borne precursors lead to the formation of histiocytic lesions. In this study, *BRAF* V600E allele-specific PCR was used to map the neoplastic clone in 20 adults with LCH ECD and HCL. *BRAF*<sup>V600E</sup> was tracked to classical monocytes, non-classical monocytes and CD1c+ myeloid DCs in the blood and mutations were observed in HSCs and myeloid progenitors in the bone marrow of 4 patients. The pattern of involvement of peripheral blood myeloid cells was indistinguishable between LCH and ECD, although the histiocytic disorders were distinct to HCL. As reported in children, detection of *BRAF*<sup>V600E</sup> in peripheral blood of adults was a marker of active multi-system LCH (MS-LCH). The healthy counterparts of myeloid cells affected by *BRAF* mutation had a range of differentiation potentials depending upon exogenous signals. CD1c+ DCs acquired high langerin and CD1a with GM-CSF and TGFβ alone while CD14+ classical monocytes required additional notch ligation. Both classical and non-classical monocytes, but not CD1c+ DCs made foamy macrophages easily in vitro with M-CSF and human serum (HS). These studies are consistent with a hematopoietic origin and more than one immediate cellular precursor, in both LCH and ECD.

**248 words**

## Introduction

Langerhans cell histiocytosis (LCH) and Erdheim Chester disease (ECD) are rare inflammatory myeloid neoplasms principally caused by mutations in the MEK-ERK signaling pathway, most commonly involving *BRAF*<sup>1-5</sup>. LCH has a peak of incidence in childhood but an increasing number of adults are now also diagnosed, including some with a poor outcome due to MS-LCH<sup>6-8</sup>. ECD, once considered a form of 'non-Langerhans' histiocytosis, appears to be a related condition by virtue of a common genetic landscape and the histological evidence of coexistent LCH and ECD in a proportion of adult patients<sup>9,10</sup>. In contrast with LCH, ECD is rarely seen in children and predominantly affects older males<sup>11,12</sup>.

In children with multi-system LCH (MS-LCH) caused by *BRAF*<sup>V600E</sup>, allele-specific PCR has been used to demonstrate mutant alleles in CD14+ and CD11c+ peripheral blood populations<sup>5</sup>. A hematopoietic origin was corroborated in two cases of MS-LCH through expansion of hematopoietic clones in vitro<sup>5</sup>. These studies support a model in which MS-LCH arises in the hematopoietic stem cell and is disseminated to the periphery by myeloid cells carrying somatic mutation<sup>13</sup>. However, the identity of blood borne cells that give rise to peripheral tissue histiocytes remains open to further investigation, since more than one cell type carries *BRAF*<sup>V600E</sup> and myeloid lineages may have overlapping differentiation potentials.

Human peripheral blood contains several subsets of myeloid mononuclear cells. Monocytes, comprise approximately 10% of mononuclear cells and may be divided into classical, non-classical and intermediate on the basis of CD14 and CD16 expression<sup>14</sup>. All human monocytes express CD11c. CD14+ classical monocytes are the most numerous and can be differentiated into macrophages and dendritic cells in vitro. Blood dendritic cells comprise 1-2% of mononuclear cells and are subdivided into CD123+ plasmacytoid DCs, and two subsets of CD11c+ myeloid DCs expressing CD1c+ and CD141+<sup>15</sup>. CD1c+ DCs are the major population of myeloid DCs in blood and tissues. They may express langerin in vivo<sup>16</sup> and readily acquire a Langerhans cell-like phenotype in vitro<sup>17,18</sup>.

The differentiation potentials of monocytes and blood DCs overlap and monocyte-derived DCs bear many markers in common with CD1c+ myeloid DCs<sup>19</sup>. Monocytes have plasticity in many directions including DC and macrophage axes<sup>20,21</sup> and may also express langerin in vitro under certain conditions<sup>22</sup>. Thus multiple blood-derived populations have the potential to contribute to histiocytic lesions.

The precursor populations of adults with LCH, ECD or LCH/ECD cross-over disease remain undefined. It is not known whether MS-LCH in adults correlates with the presence of mutant alleles in peripheral blood or if it is possible to discern a similar risk stratification in patients with ECD. *NRAS* mutation was detected in the CD14+ fraction of peripheral blood mononuclear cells in one patient<sup>23</sup> and ERK activation was reported in 1-3% of monocytes of an ECD cohort<sup>24</sup>. However, the involvement of other myeloid lineages has not been evaluated in ECD.

Recent RNA-seq suggests that LCH lesions are enriched for dendritic cell gene transcripts while biopsies of ECD are enriched for myeloid precursor and macrophage gene expression<sup>25</sup>. It has been suggested that dendritic cell pathways of development may be involved in the generation of LCH, while monocyte-macrophage differentiation could give rise to ECD. Finally, *BRAF*<sup>V600E</sup> has been detected in hematopoietic stem cells of patients with hairy cell leukemia (HCL) and confirmed by xenografting<sup>26</sup>. There does not appear to be a clinical overlap between HCL and histiocytosis and the pathogenesis of these two different conditions from a common somatic mutation, is poorly understood. HCL is therefore an interesting disease to evaluate in parallel and provides a useful control for the specificity of allele-mapping in histiocytosis.

In this report, we have analyzed the distribution of *BRAF*<sup>V600E</sup> in the peripheral blood and bone marrow progenitor compartments of adults with MS-LCH, LCH/ECD cross-over and ECD. We sought to determine whether mutant alleles could be tracked to the hematopoietic stem cell, and whether there was a correlation between the architecture of the neoplastic clone and the clinical phenotype of histiocytosis. We

also aimed to intersect these observations with studies to determine the potential of DC and monocyte lineages to generate LCH-like cells and foamy macrophages as in vitro surrogates of pathological histiocytes.

## Methods

### Patient samples, lesional *BRAF*<sup>V600E</sup> testing and clinical data

Blood, skin, bone marrow and surplus biopsy material was obtained from LCH and ECD patients referred to a local clinic with ethical approval from the Newcastle and North Tyneside Research Ethics Committee. Genomic DNA from formalin-fixed paraffin embedded LCH lesions was extracted using Promega Maxwell Tissue DNA Purification Kits (Promega; [www.promega.co.uk](http://www.promega.co.uk)) and the region flanking codon 600 amplified by PCR. Amplicons were purified and genotyped by primer extension for the c.1799T>A, p.Val600Glu (V600E) using the Sequenom iPlex protocol (Sequenom; [www.sequenom.com](http://www.sequenom.com)). The extension products were detected by MALDI-TOF Sequenom mass spectroscopy using a Sequenom Typer 4.0. Disease activity was assessed by radiological examination including magnetic resonance imaging and positron emission tomography.

### Flow cytometry

Absolute quantitation was performed using TruCount tubes on whole blood with a single step lyse no-wash protocol. For more detailed analysis, whole blood was separated by density centrifugation into mononuclear and red cell/neutrophil fractions. The red cell pellet was subsequently used for extraction of neutrophil DNA. Flow cytometry was performed on an LSRII or LSR Fortessa cytometer from Becton Dickinson (BD; [www.bd.com](http://www.bd.com)) and data analyzed with FlowJo (Treestar). Fluorescence activated cell sorting (FACS) was performed using a BD FACS Aria. Sorted cells were collected into microfuge tubes containing RPMI with 10% fetal calf serum.

Antibodies were from BD unless stated otherwise and are denoted as: antigen fluorochrome (clone). CD1a BV421 (HI149; Biolegend; [www.biolegend.com](http://www.biolegend.com)); CD1c APC (AD5-8E7; Miltenyi Biotec; [www.miltenyibiotec.com](http://www.miltenyibiotec.com)); CD3 FITC (SK7); CD3 V500 (UCHT1); CD7 FITC (4H9); CD10 PE-TR (B-Ly6; Beckman Coulter; [www.beckmancoulter.com](http://www.beckmancoulter.com)); CD11c A700 (B-ly6); CD14 APCCy7 (MΦP9); CD14 FITC (M5E2); CD16 FITC (NKP15/Leu-11a); CD16 PeCy7 (B73.1); CD19 FITC



(4G7); CD19 PEcy7 (SJ25C1); CD20 FITC (L27); CD34 PE (8G12); CD34 FITC (8G12); CD34 APC (581); CD38 PEcy7 (HB7); CD45 V450 (2D1); CD45 APCcy7 (2D1); CD45RA BV510 (HI100; Biolegend); CD56 FITC (NCAM16.2); CD90 PerCPCY5.5 (5E10; Biolegend); CD123 PerCPCY5.5 (7G3); CD123 PE (9F5); CD207 PE (DCGM4; Beckman Coulter); HLA-DR V500 (L243/G46-6); HLA-DR A700 (L243/G46-6).

### ***BRAF*<sup>V600E</sup> allele-specific PCR**

Genomic DNA from sorted blood cells, bone marrow cells control cell lines or cell-free sources was extracted using Qiagen micro-kits (Qiagen; [www.qiagen.com](http://www.qiagen.com)) *BRAF* mutation and reference qPCR was performed with competitive allele-specific Taqman® mutation detection assays: Mutation Allele Assay: *BRAF*\_476\_mu 4465804 Hs00000111\_mu; Gene Reference Assay - *BRAF*\_rf - 4465807 Hs00000172\_rf, according to the manufacturer's instructions (Life Technologies; [www.lifetechnologies.com](http://www.lifetechnologies.com)). A standard curve was derived from 6 serial dilutions of genomic DNA from *BRAF*<sup>V600E</sup> melanoma cell line A375 and EBV-transformed LCLs. 0%, 0.1% and 10% V600E mutation controls were performed with every run. The percentage of *BRAF*<sup>V600E</sup> mutation was determined from the dCT (CTreference-CTmutant) using the standard curve. Graphs were plotted with Prism Version 5.0 (GraphPad Software, Inc.).

### **In vitro differentiation**

Aliquots of 10,000 sorted cells from healthy controls were cultured in RPMI 1640 with 10% fetal bovine serum or 5% human serum in 100µl in 96-well plates. Supplements were added at: GM-CSF 50 ng/µl; TGFβ, 10 ng/µl; M-CSF 50 ng/µl. Cultures were maintained for 3 days before analysis by flow cytometry. For phase contrast microscopy, cells were cultured in Thermo Scientific Nunc chamber slides System for 7 days, washed gently and fixed with 1% paraformaldehyde in PBS and images acquired with Carl Zeiss Axioplan 2 x40 objective and Carl Zeiss Axiovision software release 4.8

## **Statistical methods**

Mann Whitney tests, t-tests and Fisher's exact test were performed using GraphPad Prism 5.0 software.

## Results

Fifty-two adults with histiocytosis and 4 with HCL were recruited from a local clinic and collaborating centers (**Figure 1**). Twenty with histiocytosis and all with HCL had confirmed  $BRAF^{V600E}$  lesions. Three additional children with  $BRAF^{V600E}$ -mutated LCH were included in some analyses for comparison. Further clinical details are given in **Supplementary Table 1**.

Detection of  $BRAF^{V600E}$  was performed using an allele-specific PCR and was sensitive to 0.01% with a quantitative range to 0.1% (**Figure 2A**).  $BRAF^{V600E}$  alleles were detectable in DNA isolated from PBMC of patients with active multi-system LCH with or without co-existent ECD (LCH/ECD cross-over), but were only present in one patient with SS LCH (**Figure 2B**). ECD is not conventionally classified into SS or MS. Nearly all cases involved multiple systems. There was no clear correlation between clinical features and  $BRAF^{V600E}$  detection the PBMC (see **Supplementary Table 1** for details)

A simple linear correlation was observed between the frequency of mutant allele detection in PBMC vs. cell-free plasma DNA, with approximately half-log greater sensitivity for detection in cellular DNA (**Figure 2C**). In order to exclude the uptake of free DNA into the cell-associated pool by phagocytosis or macropinocytosis, purified  $BRAF^{V600E}$  mutated DNA from A375 cells was incubated with whole blood of healthy controls (**Figure 2Di**) and sorted cell fractions were cultured with medium containing 20% serum from a patient with HCL (**Figure 2Dii**). Cellular and cell-free DNA was then recovered and subjected to PCR. Mutated  $BRAF$  alleles were only recovered from the cell-free fraction, but not the cellular DNA, indicating that uptake of exogenous DNA did not account for cell-associated  $BRAF^{V600E}$ . With patient serum, cell cultures not only remained negative but diluted or degraded the cell-free signal.

The pattern of mononuclear cells observed by flow was analyzable by conventional gating and no atypical populations were detected (**Supplementary Figure 1**).

Neither langerin+CD1a+ LCH-like cells nor CD103+ CD11c+ hairy cells were detectable in any of the histiocytosis patients (**Supplementary Figure 1**). Absolute counting of PBMC from patients with histiocytosis revealed monocytosis and increased numbers of total CD11c+ and CD11c+CD1c- myeloid cells (**Supplementary Figure 1,2**). There were no detectable differences between *BRAF* mutated and WT disease although power to detect subgroup differences was limited. No cytological atypia was observed among monocytes and DC subsets (**Supplementary Figure 3**).

In order to map the distribution of mutant alleles, PBMC from 9/11 patients with circulating *BRAF*<sup>V600E</sup> and 2 children with MS-LCH, were fractionated into four quadrants according to the expression of HLA-DR and lineage (CD3, CD19, CD20 and CD56). The gates were completely apposed in order to account for all mutant alleles present in PBMC and to exclude the inadvertent loss of signal to an uncharacterized disease-related population.

In contrast to patients with HCL, in which *BRAF*<sup>V600E</sup> was largely confined to the HLA-DR+ lineage+ quadrant containing hairy cells, mutation in patients with histiocytosis was highly enriched in the HLA-DR+ lineage- quadrant containing monocytes and DCs (**Figure 3A**). Some overspill into adjacent quadrants was observed, owing to the close gating. For example, in histiocytosis patients, positivity appeared in the HLA-DR- lineage- quadrant. This was further studied in case A2951 and found to be associated with CD14+ monocytes and CD11c+ myeloid precursors expressing low HLA-DR at the top of the double negative gate (data not shown).

The mononuclear compartment was further fractionated to explore the distribution of mutant alleles at higher resolution (**Supplementary Figure 1, 2; Figure 3B**). As expected, *BRAF*<sup>V600E</sup> was localized to hairy cells with a low level of alleles detectable in phenotypically normal B and NK cells but none in the remaining monocytes and myeloid cells. In contrast, the majority of alleles in patients with histiocytosis were found in CD14+ classical monocytes, CD16+ non-classical monocytes and CD11c+ CD1c+ myeloid DCs. Plasmacytoid DCs harbored some alleles in LCH patients and

in one case  $BRAF^{V600E}$  was also detectable at a low level in B and T cells. The distribution of alleles did not vary significantly between LCH, ECD and patients with LCH/ECD. In addition to these compartments, we studied CD14+CD16+ intermediate monocytes and CD11c+CD1c- myeloid cells in a subset of patients (see **Supplementary Figures 1,2,4** for details). These did not differ significantly from the allele level in CD14+ classical monocytes and CD1c+ myeloid DC, respectively.

$BRAF^{V600E}$  mutation was previously reported in children with MS-LCH, using a more simple gating strategy to obtain CD14+ and CD11c+ myeloid cells <sup>5</sup>. CD11c+ myeloid cells comprise multiple fractions including CD1c+ myeloid DCs, CD16+ non-classical monocytes and CD11c+CD1c- cells which were analyzed separately here. The relationship between these populations is summarized in **Supplementary Figure 4**.

In order to probe the hematopoietic origin of LCH and ECD, bone marrow was analyzed from 2 patients with multi-system LCH and 2 with ECD. One ECD patient (A7344) had mutated *NRAS* rather than *BRAF* and was previously reported to have a high level of *NRAS* mutation in CD14+peripheral blood monocytes (A7344) <sup>23</sup>. A commonly used schema for immunophenotyping (**Supplementary Figure 5**), revealed that the common myeloid progenitor (CMP) and granulocyte-macrophage progenitor (GMP) compartments were relatively expanded (**Figure 4A**).  $BRAF^{V600E}$  was detectable in CD90+ CD45RA- CD38low hematopoietic stem cells, CD38high CD45RA- CMP and CD45RA+ GMP (**Figure 4B**). The mutant allele was present at <1% in HSCs and was most enriched in the CMP fraction. Mature histiocytes arising from the mutated clone were rigorously excluded in this analysis (**Supplementary Figure 5**). A pediatric patient included for comparison showed a similar distribution of alleles. The *NRAS* mutated patient was quantified by peak height on Sanger sequencing at 21-63% in myeloid precursor fractions. Progenitor cells from this patient were demonstrated to engraft in immunodeficient mice, in the accompanying paper.

These results suggest that LCH and ECD arise in the hematopoietic stem cell and that are transmitted to peripheral tissues by blood-borne myeloid cells. However, there was no obvious disease-specific bias in the distribution of mutant alleles among myeloid cells, that might correlate phenotypic differences between LCH and ECD. We therefore evaluated the potential of each myeloid fraction to give rise to the characteristic cells of LCH and ECD lesions through in vitro differentiation of sorted fractions from healthy controls.

It has previously been demonstrated that monocytes and CD1c+ DCs can express langerin in vitro under different conditions but only cells with high langerin and CD1a contain Birbeck granules<sup>17,18,22,27,28</sup>. Previous reports are discordant and have not examined monocytes and DCs from peripheral blood and compared their differentiation capacity in the same platform. We therefore tested the development of an LC-like phenotype by blood monocytes and CD1c+ DCs using conditions that had been previously described in either monocytes or DCs<sup>17,18,22,27,28</sup>: soluble factors GM-CSF and TGF $\beta$  and the notch ligands DLL1 and DLL4, expressed on mouse OP9 cells. In order to study the potential to develop foamy macrophage morphology, we used M-CSF with 5% human serum.

As shown previously, CD1c+ DCs attained high langerin expression with GM-CSF and TGF- $\beta$  alone. Soluble factors GM-CSF and TGF- $\beta$ , were not sufficient to induce high langerin in CD14+ monocytes but this potential was revealed by co-culture with notch ligands DLL1 and DLL4. CD16+ monocytes did not express high langerin under any conditions but notch ligation also further enhanced the expression of langerin by CD1c+ DCs in response to soluble factors (**Figure 5 and Supplementary Figure 6**). In macrophage differentiation conditions, CD1c+ DCs were unable to form foam cells while both monocyte subsets developed this phenotype. A summary of the distribution of *BRAF* alleles and differentiation potential of myeloid lineage affected is shown in **Table 1**.

## Discussion

Prior to the discovery of *BRAF*<sup>V600E</sup> there was accumulating evidence that both LCH and ECD were clonal proliferations of histiocytes, including a remarkable insight by Chetrit and colleagues that ECD was the 'macrophage counterpart to LCH' <sup>29,30</sup>. Here we have exploited the recurrent *BRAF*<sup>V600E</sup> mutation to map the neoplastic clones of LCH and ECD. The results further reinforce the concept that LCH and ECD are closely related hematopoietic neoplasms, regardless of their distinctive pathological features <sup>31</sup>.

A high resolution analysis of myeloid cells demonstrated the highest frequency of mutant alleles in CD14+ classical monocytes, CD16+ non-classical monocytes and CD1c+ myeloid DCs. Unexpectedly, the non-classical monocyte is a reservoir of *BRAF* mutation and accounts for a proportion of the signal previously tracked to CD11c+ myeloid cells<sup>5</sup>. We also mapped *BRAF* mutation to cells defined by phenotype as HSCs in LCH, ECD and HCL. *BRAF*<sup>V600E</sup> has previously been reported in HSCs of children with MS-LCH <sup>5</sup> and patients with HCL <sup>26</sup> and it remains unclear how the same mutation present in HSCs generates such unrelated pathologies. Although there is a documented overlap between LCH and ECD <sup>9,10</sup> HCL is unrelated in incidence and we did not observe HCL leukocytes in any patient with histiocytosis.

The initial cell sorting approach adopted apposed gating of the HLA-DR vs. lineage plot of total PBMC in order to account for all the mutated alleles present in PBMC DNA (neutrophils were consistently negative). Although we localized most of the *BRAF*<sup>V600E</sup> alleles in peripheral blood to the HLA-DR+ lineage- compartment of both LCH and ECD, some overspill was observed into the HLA-DR- lineage- cells, owing to this strategy. While a proportion of this signal was contained in HLA-DR<sup>lo</sup> CD14+ monocytes, CD11c+ CD1c- myeloid progenitors that may generate macrophages and are also found in this region. In particular, ECD patients frequently have expanded myelopoiesis with an element of left-shift that mobilizes these cells into the peripheral compartment; thus we cannot exclude a contribution of more primitive

myeloid precursors to the lesions of ECD. Notably, recent gene expression studies described enrichment for myeloid progenitor signatures in ECD lesions<sup>25</sup>.

There is significant interest in cell-free DNA as a marker of neoplasia and this is also detectable in histiocytosis<sup>32</sup>. In our hands, plasma cell-free *BRAF*<sup>V600E</sup> was approximately half-log lower in abundance than cell-associated alleles. We considered the possibility that exogenous DNA might account for the mutant alleles found in PBMC, especially as the signal was localized to monocytes with phagocytic activity. However, exposure of healthy control blood to *BRAF* mutated genomic DNA did not result in a cell-associated signal. Furthermore, the lack of mutated alleles in neutrophils but the localization of mutation to non-phagocytic CD34+ progenitor cells, argue against phagocytic uptake of exogenous DNA as a significant source of artifact.

Total RNA profiling reveals a strong DC-related and macrophage-related signature in LCH and ECD, respectively<sup>25</sup>. However, there was no bias in the distribution of mutated alleles to suggest that the phenotypic differences of LCH and ECD lesions are determined by the myeloid lineages harboring *BRAF* mutation. This may not be surprising given the relatively high incidence of overlap cases now documented<sup>9,10</sup>. Many alternatives may explain the variation between LCH and ECD, such as genetic background, age-related myeloid hematopoietic bias<sup>33</sup>, additional somatic mutation<sup>34</sup> or extrinsic inflammatory signals arising independently in the local tissue environment. The difference in median age of onset between LCH and ECD is consistent with an influence of age-related myeloid bias or clonal hematopoiesis. From a pathological perspective, the occurrence of LCH and ECD together in a single lesion, suggests a cell-intrinsic mechanism<sup>10</sup>. However, in cases where an overlap syndrome occurs with distinct and characteristic anatomical distributions of each disease, the tissue environment may direct either LCH or ECD-like pathology, through extrinsic signals. In keeping with previous reports of expanded myelopoiesis in MS-LCH<sup>35</sup>, we observed an increase in blood myeloid cells and BM myeloid progenitors in adult LCH and ECD.



The differentiation of myeloid cells in response to cytokine and notch-mediated signaling showed that more than one precursor has the potential to form cells with characteristic properties of LCH and ECD histiocytes. The critical role of notch signaling in permitting LC development from monocytes was first reported in response to delta-like protein 1 (DLL1)<sup>22</sup>. Without this signal, CD14<sup>+</sup> classical monocytes only express low langerin and are unable to form Langerin<sup>high</sup> CD1a<sup>+</sup> cells containing Birbeck granules, in response to GM-CSF and TGF $\beta$ . In contrast, CD1c<sup>+</sup> DCs spontaneously express langerin in vivo<sup>16</sup> and rapidly acquire LC-like properties when exposed to GM-CSF and TGF $\beta$ <sup>17,18</sup>. In vitro differentiation experiments presented here clearly show that two pathways may generate langerin<sup>high</sup> cells and that delta-like protein 4 (DLL4) provides a more potent signal for monocytes than DLL1. Recent molecular studies have shown that DLL1 induces LC development in monocytes by down-regulating KLF and de-repressing RUNX3<sup>28</sup>. Elevated GM-CSF, M-CSF and FLT3 ligand have been reported in the serum of patients with LCH, consistent with a pathological role of these cytokines<sup>35,36</sup>. Intrinsic notch signaling was previously suggested as a key mechanism promoting LCH pathogenesis, through expression of Jagged 2 by lesional histiocytes<sup>27</sup>. Taken together, these observations do not support a simple dichotomous model that LCH arises from the DC pathway and ECD from the monocyte-macrophage pathway of myeloid cell development. Classical monocytes appear able to contribute to histiocytes of both disorders, depending upon the signals they receive. CD1c<sup>+</sup> DCs, on the other hand, were unable to form foamy macrophages when exposed to strongly macrophage promoting conditions of M-CSF and lipid-containing human serum. Both classical and non-classical monocytes rapidly differentiated into typical foam cells under these conditions. CD16<sup>+</sup> non-classical monocytes are likely to be heterogeneous and have also been characterized as DC-like<sup>37,38</sup>. It is possible that a subpopulation formed the macrophages observed in culture as the final density was lower than for equivalent numbers of CD14<sup>+</sup> monocytes. Given the high proportion of *BRAF* mutated alleles in CD16<sup>+</sup> monocytes, they may contribute to histiocytes in the lesions of ECD, although they are reported to be unable to form giant cells. The occurrence of mutated alleles in monocytes also presents the possibility that macrophages in LCH lesions arise from the neoplastic clone.

Previous studies show that M-CSF, one of the factors used to differentiate foam cells, is significantly increased in MS-LCH<sup>35</sup>

An important caveat of the in vitro differentiation experiment is that healthy control cells without *BRAF* mutation were used. In the absence of a surface antigen that can distinguish mutated and unmutated progeny, this analysis cannot be performed with enriched *BRAF*-mutated cells isolated from patients. The presence of mutation may not matter since ERK activation is a consequence of many of the stimuli used in vitro. However, it remains hypothetically possible that intrinsic *BRAF* activation has other unanticipated effects.

The finding that *BRAF* mutated PBMC are detected at higher level in MS-LCH has potential utility as an indicator of clinical risk and response to therapy, as suggested in children<sup>5</sup>. Our conclusion in adults is based on only 8 patients and should be expanded to a larger cohort, ideally. The sensitivity of detection using allele-specific PCR is critical as less sensitive techniques failed to find *BRAF* mutation in peripheral blood or bone marrow fractions previously<sup>2,4</sup>. *BRAF*<sup>V600E</sup> was detected in PBMC of a subset of ECD patients and it remains to be determined, using a large group, whether this segregates with disease risk in ECD.

## Acknowledgement

This research was funded by Cancer research UK grant C30484/A21025, the Histiocytosis Association and Bright Red. VB is supported by a Wellcome Trust Intermediate Clinical Fellowship 101155/Z/13/Z and MH by a Wellcome Trust Senior Clinical Fellowship WT088555MA. SB was supported by a NIHR Clinical Lectureship. BD is supported by the American Society of Hematology Senior Research Training Award for Fellows and the New York State Council on Graduate Medical Education Empire Clinical Research Investigator Program Fellowship. ELD and OAW are supported by grants from the Erdheim Chester Disease Global Alliance and the Histiocytosis Association. We are grateful to Dr Andrew Filby and the Newcastle University Flow Cytometry Core Facility for assistance with the

generation of flow cytometry data and to Dr Alex Laude and the Bioimaging core for assistance with microscopy.

## Authorship

Paul Milne designed research, performed experiments, analyzed data and wrote the paper

Venetia Bigley designed research, analyzed data and contributed clinical data and patient material

Chris M Bacon designed research, performed experiments and analyzed data

Antoine Neel contributed clinical data and patient material

Naomi McGovern performed experiments and analyzed data

Simon Bomken contributed clinical data and patient material

Muzlifah Haniffa designed research and contributed clinical data and patient material

Eli Diamond contributed clinical data and patient material

Ben Durham contributed clinical data and patient material

Johann Visser contributed clinical data and patient material

David Hunt contributed clinical data and patient material

Harsha Gunawardena contributed clinical data and patient material

Mac Macheta contributed clinical data and patient material

Kenneth McClain designed research

Carl Allen designed research

Omar Abdel-Wahab designed research and contributed clinical data and patient material

Matthew Collin supervised the study, designed research, analyzed data and wrote the paper

## Disclosures

The authors have no conflicts of interest to disclose

## References

1. Badalian-Very G, Vergilio JA, Degar BA et al. Recurrent *BRAF* mutations in Langerhans cell histiocytosis. *Blood*. 2010;116 (11):1919-1923.
2. Sahm F, Capper D, Preusser M et al. *BRAF*V600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. *Blood*. 2012;120 (12):e28-34.
3. Haroche J, Charlotte F, Arnaud L et al. High prevalence of *BRAF* V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. *Blood*. 2012;120 (13):2700-2703.
4. Satoh T, Smith A, Sarde A et al. B-Raf mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. *PLoS One*. 2012;7 (4):e33891.
5. Berres ML, Lim KP, Peters T et al. *BRAF*-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. *J Exp Med*. 2014;211 (4):669-683.
6. Arico M, Girschikofsky M, Genereau T et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. *Eur J Cancer*. 2003;39 (16):2341-2348.
7. Teng CL, Lin TH, Young JH, Chou G, Young CS. Rapidly fatal Langerhans' cell histiocytosis in an adult. *J Formos Med Assoc*. 2005;104 (12):955-959.
8. Girschikofsky M, Arico M, Castillo D et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. *Orphanet J Rare Dis*. 2013;8 72.
9. Yin J, Zhang F, Zhang H et al. Hand-Schuller-Christian disease and Erdheim-Chester disease: coexistence and discrepancy. *Oncologist*. 2013;18 (1):19-24.
10. Hervier B, Haroche J, Arnaud L et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the *BRAF*V600E mutation. *Blood*. 2014;124 (7):1119-1126.
11. Diamond EL, Dagna L, Hyman DM et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. *Blood*. 2014;124 (4):483-492.

12. Haroche J, Arnaud L, Cohen-Aubart F et al. Erdheim-Chester disease. *Curr Rheumatol Rep.* 2014;16 (4):412.
13. Collin M, Bigley V, McClain KL, Allen CE. Cell(s) of Origin of Langerhans Cell Histiocytosis. *Hematol Oncol Clin North Am.* 2015;29 (5):825-838.
14. Ziegler-Heitbrock L, Ancuta P, Crowe S et al. Nomenclature of monocytes and dendritic cells in blood. *Blood.* 2010;116 (16):e74-80.
15. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. *Immunology.* 2013;140 (1):22-30.
16. Bigley V, McGovern N, Milne P et al. Langerin-expressing dendritic cells in human tissues are related to CD1c+ dendritic cells and distinct from Langerhans cells and CD141high XCR1+ dendritic cells. *J Leukoc Biol.* 2015;97 (4):627-634.
17. Martinez-Cingolani C, Grandclaude M, Jeanmougin M, Jouve M, Zollinger R, Soumelis V. Human blood BDCA-1 dendritic cells differentiate into Langerhans-like cells with thymic stromal lymphopoietin and TGF-beta. *Blood.* 2014;124 (15):2411-2420.
18. Milne P, Bigley V, Gunawan M, Haniffa M, Collin M. CD1c+ blood dendritic cells have Langerhans cell potential. *Blood.* 2015;125 (3):470-473.
19. Manh TP, Alexandre Y, Baranek T, Crozat K, Dalod M. Plasmacytoid, conventional and monocyte-derived dendritic cells undergo a profound and convergent genetic reprogramming during their maturation. *Eur J Immunol.* 2013;pub ahead of print.
20. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. *Nat Immunol.* 2000;1 (6):510-514.
21. Xue J, Schmidt SV, Sander J et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. *Immunity.* 2014;40 (2):274-288.
22. Hoshino N, Katayama N, Shibasaki T et al. A novel role for Notch ligand Delta-1 as a regulator of human Langerhans cell development from blood monocytes. *J Leukoc Biol.* 2005;78 (4):921-929.
23. Emile JF, Diamond EL, Helias-Rodzewicz Z et al. Recurrent RAS and PIK3CA

- mutations in Erdheim-Chester disease. *Blood*. 2014;124 (19):3016-3019.
24. Cangi MG, Biavasco R, Cavalli G et al. *BRAF*V600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. *Ann Rheum Dis*. 2015;74 (8):1596-1602.
  25. Diamond EL, Durham BH, Haroche J et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. *Cancer Discov*. 2016;6 (2):154-165.
  26. Chung SS, Kim E, Park JH et al. Hematopoietic Stem Cell Origin of *BRAF*V600E Mutations in Hairy Cell Leukemia. *Sci Transl Med*. 2014;6 (238):238ra71.
  27. Hutter C, Kauer M, Simonitsch-Klupp I et al. Notch is active in Langerhans cell histiocytosis and confers pathognomonic features on dendritic cells. *Blood*. 2012;120 (26):5199-5208.
  28. Jurkin J, Krump C, Köffel R et al. Human skin dendritic cell fate is differentially regulated by the monocyte identity factor KLF4 during steady state and inflammation. *J Allergy Clin Immunol*. 2016
  29. Willman CL, Busque L, Griffith BB et al. Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. *N Engl J Med*. 1994;331 (3):154-160.
  30. Chetritt J, Paradis V, Dargere D et al. Chester-Erdheim disease: a neoplastic disorder. *Hum Pathol*. 1999;30 (9):1093-1096.
  31. Emile JF, Abla O, Fraitag S et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. *Blood*. 2016
  32. Janku F, Vibat CR, Kosco K et al. *BRAF* V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. *Oncotarget*. 2014;5 (11):3607-3610.
  33. Geiger H, de Haan G, Florian MC. The ageing haematopoietic stem cell compartment. *Nat Rev Immunol*. 2013;13 (5):376-389.
  34. Jaiswal S, Fontanillas P, Flannick J et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371 (26):2488-2498.
  35. Rolland A, Guyon L, Gill M et al. Increased blood myeloid dendritic cells and dendritic cell-poitins in Langerhans cell histiocytosis. *J Immunol*. 2005;174 (5):3067-3071.

36. Emile JF, Tartour E, Brugières L et al. Detection of GM-CSF in the sera of children with Langerhans' cell histiocytosis. *Pediatr Allergy Immunol.* 1994;5(3):162-163.
37. MacDonald KP, Munster DJ, Clark GJ, Dzionek A, Schmitz J, Hart DN. Characterization of human blood dendritic cell subsets. *Blood.* 2002;100(13):4512-4520.
38. Piccioli D, Tavarini S, Borgogni E et al. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. *Blood.* 2007;109(12):5371-5379.

## Table legend

### Table 1

Table summarizing *BRAF*<sup>V600E</sup> mutant allele frequency among blood monocytes and myeloid DCs (data from Figure 3) and the potential of wild-type cells to form langerin high LCH-like cells or foamy macrophages in vitro. Frequency of langerin high indicated as follows: - <10%; + 10-25%; ++ 26-35% and +++ >35 %

## Figure legends

### Figure 1. Patients

Summary of adult patients included in the study. WT wild-type; NT not tested; LCH Langerhans cell histiocytosis; ECD Erdheim Chester Disease; HCL Hairy Cell Leukemia. Asterisks indicate the number of patients with *BRAF*<sup>V600E</sup> detectable in PBMC. The *BRAF* wild type ECD group includes one patient with *RAS* mutation

### Figure 2. Detection of *BRAF*<sup>V600E</sup> alleles

- A. A standard curve constructed using DNA purified from a dilution series of *BRAF*<sup>V600E</sup> positive melanoma cell line A375 into wild-type Epstein-Barr virus (EBV) transformed lymphoblastoid cell line. The quantitative limit detection was 0.1%; the absolute limit of detection was 0.01% (POQR).
- B. *BRAF*<sup>V600E</sup> allele frequency in bulk PBMC in cases of lesion *BRAF*<sup>V600E</sup>+ LCH, LCH/ECD and ECD. Contingency of positive PBMC upon multisystem LCH tested by Fisher's exact test.
- C. Correlation between mutated allele burden in cell-free plasma and PBMC DNA in LCH, ECD and HCL.



- D. I. Test of exogenous free DNA uptake by PBMC. *BRAF* mutated DNA (derived from melanoma cell line A375 was spiked into whole blood for 24 hours at room temperature. Plasma and PBMC were isolated by density centrifugation. DNA was extracted from both fractions and subjected to allele-specific PCR.
- II. Test of exogenous free DNA uptake by sorted cells incubated at 37°C for 24 hours in medium supplemented with 20% human serum from a patient with hairy cell leukemia. DNA from supernatants and cell pellets, as indicated, was subjected to allele-specific PCR.

**Figure 3. Allele-specific PCR of *BRAF*<sup>V600E</sup> in PBMC**

- A. The distribution *BRAF*<sup>V600E</sup> in PBMC sorted into quadrants as shown according to expression of HLA-DR and lineage. Pie charts summarize the distribution of mutant alleles in HCL, LCH and ECD. The area of each quadrant in the pie is proportional to the total number of mutant alleles in that quadrant (i.e the percentage positivity of the quadrant multiplied by the number of cells in the quadrant). All patients had active disease at the time of sampling. Two children with LCH included for comparison, are indicated. \*Indicates the threshold of detection for a negative result where cell numbers were limiting.
- B. The distribution *BRAF*<sup>V600E</sup> among peripheral blood cells showing the % mutated alleles detected. NT = not tested owing to lack of or insufficient material. \* Child with MS-LCH shown for comparison. All patients had active disease at the time of sampling. Italics indicate those who had received prior treatment.

**Figure 4. Mononuclear profile and *BRAF* allele frequency in CD34+ BM progenitors**

- A. Relative proportions of progenitor fractions among CD34+ bone marrow mononuclear cell compared with healthy controls (n=21), expressed as percentage of total live cells. Error bars depict 95% confidence intervals of healthy controls. Populations: HSC: Hematopoietic stem cells; LMPP: lymphoid-primed multi-potent progenitors; B/NK: B/NK cell progenitors; CMP: common

myeloid progenitors; GMP: granulocyte/macrophage progenitors. MPP: multipotent progenitor.

- B. The distribution  $BRAF^{V600E}$  among  $CD34^+$  bone marrow progenitors. BM aspirate was obtained in parallel with the peripheral blood shown previously. NT = not tested owing to insufficient number of cells.

### **Figure 5. in vitro differentiation potential of monocytes and myeloid DCs**

- A. Sorted  $CD14^+$  monocytes,  $CD16^+$  monocytes and  $CD1c^+$  myeloid DCs from healthy controls cultured for 3 days in conditions as shown. Langerin high  $CD1a^+$  gates depicted contain LCH-like cells with Birbeck granules. Notch ligands DLL1 And DLL4 were presented on transfected mouse OP9 cells. Representative data of 5 independent experiments.
- B. Sorted  $CD14^+$  monocytes,  $CD16^+$  monocytes and  $CD1c^+$  myeloid DCs from healthy controls cultured for 7 days with M-CSF and 5% human serum (HS) to reveal potential to differentiate into foamy macrophages. Representative phase contrast images of 5 independent experiments..

### **Figure 6. Potential precursor pathways in MS-LCH and ECD**


Schema summarizing potential precursor pathways in MS-LCH and ECD based on the distribution of  $BRAF^{V600E}$  alleles in peripheral blood and the differentiation potentials of healthy control cells in vitro. A minority of cells (filled) in the BM and blood contain  $BRAF$  mutation. The principal observation is that <1% clonal haematopoiesis gives rise to <3% mutated blood precursors that appear to be strongly selected for in peripheral tissue environments, resulting in lesional histiocyte mutation levels of up to 100%. Lesions potentially consist of more than one precursor as indicated by blue for  $CD1c^+$  DC, red for classical monocyte and brown for non-classical monocytes. The depiction of lesion composition is conjectural and not based upon experimental observation. Furthermore, additional contributions from other more primitive myeloid progenitors, cannot be excluded at present.


Abbreviations: HCL: hairy cell leukemia; LCH: Langerhans cell histiocytosis; ECD: Erdheim Chester disease


**Table 1**


|                                | CD14 | CD16 | CD1c |
|--------------------------------|------|------|------|
| % <i>BRAF</i> <sup>V600E</sup> |      |      |      |
| median                         | 0.38 | 1.36 | 0.2  |
| range                          | 0-18 | 0-45 | 0-8  |
|                                |      |      |      |
| Langerin+ potential            |      |      |      |
| GM-CSF +TGFβ                   | -    | -    | ++   |
| +DLL1                          | +    | -    | +++  |
| +DLL4                          | +++  | -    | +++  |
|                                |      |      |      |
| Foamy mac potential            | +++  | +++  | -    |

**Figure 1**





**Figure 2**

**Figure 3**

**Figure 4****A****B**


|     |          | HSC   | CMP   | GMP   | LMPP | B/NK | HCL   |
|-----|----------|-------|-------|-------|------|------|-------|
| HCL | A7264    | 0.57  | 0.07  |       | 0.05 |      | 33.37 |
| LCH | ▲ A2712  | 0.47  | 4.56  | 0.61  | 0.00 | 0.00 | N/A   |
|     | ■ A2951  | 0.61  | 12.67 | 1.33  | 0.20 | 0.00 | N/A   |
|     | ▼ A8086* | 0.15  | 0.29  | 0.85  | 0.05 | 0.03 | N/A   |
| ECD | ● A7791  | 0.10  | 0.35  | 0.48  | 0.01 | NT   | N/A   |
|     | ◆ A7344† | 29.00 | 21.00 | 63.00 | 0.00 | 0.00 | N/A   |

\*child †NRAS<sup>Q61R</sup> Sanger Sequencing

**Figure 5****B M-CSF + 5% HS**



**Figure 6**





Prepublished online May 16, 2017;  
doi:10.1182/blood-2016-12-757823

## **Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester disease in adults**

Paul Milne, Venetia Bigley, Chris M. Bacon, Antoine Néel, Naomi McGovern, Simon Bomken, Muzlifah Haniffa, Eli L. Diamond, Benjamin H. Durham, Johannes Visser, David Hunt, Harsha Gunawardena, Mac Macheta, Kenneth L. McClain, Carl Allen, Omar Abdel-Wahab and Matthew Collin

---

Information about reproducing this article in parts or in its entirety may be found online at:  
[http://www.bloodjournal.org/site/misc/rights.xhtml#repub\\_requests](http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests)

Information about ordering reprints may be found online at:  
<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:  
<http://www.bloodjournal.org/site/subscriptions/index.xhtml>

---

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.